Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
A Pilot study on circulating tumor DNA (ctDNA) in advanced/metastatic breast cancer with low levels of HER2 expression (HER2 low)
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjentki z rakiem piersi HER2-low (niski poziom białka HER2).
- •Rak jest w zaawansowanym stadium lub rozsiany przed rozpoczęciem leczenia.
- •Pacjentki muszą wyrazić świadomą zgodę na udział w badaniu.
- •Możliwość śledzenia stanu pacjentki po włączeniu do badania.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- March 24, 2026
- Sex
- Female only
Locations (1)
European Institute of Oncology
Milan, Italy
Trial contact
Nicola Fusco, MD
francesca lombardi, biologist
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.